alexa Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance.

Journal of Thrombosis and Circulation: Open Access

Author(s): Cattaneo M, Schulz R, Nylander S

Abstract Share this page

Abstract This review constitutes a critical evaluation of recent publications that have described an additional mode of action of the P2Y12 receptor antagonist ticagrelor. The effect is mediated by inhibition of the adenosine transporter ENT1 (type 1 equilibrative nucleoside transporter), which provides protection for adenosine from intracellular metabolism, thus increasing its concentration and biological activity, particularly at sites of ischemia and tissue injury where it is formed. Understanding the mode of action of ticagrelor is of particular interest given that its clinical profile, both in terms of efficacy and adverse events, differs from that of thienopyridine P2Y12 antagonists. Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. This article was published in J Am Coll Cardiol and referenced in Journal of Thrombosis and Circulation: Open Access

Relevant Expert PPTs

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version